AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

Zemcelpro provides an option for people with a hematologic malignancy who need a blood stem cell transplant but have no ...

AbbVie (ABBV) said on Monday that its late-stage trial evaluating its drug Venetoclax in combination with Azacitidine in the ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The drugmaker ...

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited ...

Myelodysplastic syndromes (MDS) are a group of disorders that typically arise in adulthood, especially after the age of 70, ...

Experts reassess endpoints, patient selection, targets, and timing for the development of successful immune-based treatments ...